Cardiovascular and Periodontal Study: a randomised controlled trial
Active, not recruiting
- Conditions
- Periodontal diseaseCardiovascular diseaseCardiovascular - Other cardiovascular diseasesOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
- Registration Number
- ACTRN12605000593639
- Lead Sponsor
- Oral Care Research Programme, The University of Queensland
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
Ecidence of myocardial infarction within the previous 3 years, recent events within the previous 3 years - episodes of unstable angina, admission to hospital, abnormal cardiogram.
Exclusion Criteria
No exclusion criteria
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression of periodontal disease in the triclosan versus placebo groups[Measured annually]
- Secondary Outcome Measures
Name Time Method Changes in serum lipid profiles[Measured at yearly intervals.];Inflammatory markers[Measured at yearly intervals.];Anti-HSP 60 and anti Pg-GroEL antibodies and periodontal bacteria[Measured at yearly intervals.];To determine if the primary outcome is influenced by genotype.<br>[]
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways does triclosan in dentifrice modulate to link periodontal and cardiovascular health in ACTRN12605000593639?
How does triclosan-containing dentifrice compare to mechanical debridement in reducing cardiovascular risk markers for periodontitis patients?
Which inflammatory biomarkers (e.g., CRP, IL-6) predict response to triclosan dentifrice in ACTRN12605000593639's cardiovascular outcomes?
What adverse events were observed with triclosan dentifrice in ACTRN12605000593639, and how do they compare to chlorhexidine-based therapies?
Are there synergistic effects of triclosan dentifrice with statins or anti-inflammatory agents in managing periodontal-cardiovascular disease interplay?